Jorge Correia.

Jorge Correia, Ph.D., is a Principal Scientist at Novo Nordisk since June 2022, specializing in neuromuscular and metabolic diseases. Previously, Jorge worked at Karolinska Institutet from November 2011 to June 2022 as a Researcher and Postdoctoral Research Fellow, focusing on transcriptional regulation of skeletal muscle mass and inter-organ communication. Earlier experience includes serving as a Visiting Ph.D. Student, conducting research related to the regulation of liver metabolism by bile acid receptor splice isoforms. Jorge completed a Doctor of Philosophy in Molecular and Cellular Biology and holds a Biochemistry Degree, both from Universidade do Algarve, where Jorge also worked as a Ph.D. Student from February 2009 to May 2014.